User profiles for Zhiqiang Wu
 | Zhiqiang WuBrage Golding Distinguished Professor of Electrical Engineering, Wright State University Verified email at wright.edu Cited by 5352 |
Virome analysis for identification of novel mammalian viruses in bat species from Chinese provinces
Bats are natural hosts for a large variety of zoonotic viruses. This study aimed to describe
the range of bat viromes, including viruses from mammals, insects, fungi, plants, and phages, …
the range of bat viromes, including viruses from mammals, insects, fungi, plants, and phages, …
[HTML][HTML] New development in CAR-T cell therapy
Z Wang, Z Wu, Y Liu, W Han - Journal of hematology & oncology, 2017 - Springer
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded unprecedented
efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells for B cell …
efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells for B cell …
High-performance MC-CDMA via carrier interferometry codes
…, S Shattil, M Michelini, Z Wu - IEEE Transactions …, 2001 - ieeexplore.ieee.org
This paper introduces the principles of interferometry to multicarrier code division multiple
access (MC-CDMA). Specifically, we propose the use of MC-CDMA with novel carrier …
access (MC-CDMA). Specifically, we propose the use of MC-CDMA with novel carrier …
Deciphering the bat virome catalog to better understand the ecological diversity of bat viruses and the bat origin of emerging infectious diseases
Studies have demonstrated that ~60%–80% of emerging infectious diseases (EIDs) in humans
originated from wild life. Bats are natural reservoirs of a large variety of viruses, including …
originated from wild life. Bats are natural reservoirs of a large variety of viruses, including …
Ultra‐broadband strong electromagnetic interference shielding with ferromagnetic graphene quartz fabric
Flexible electromagnetic interference (EMI) shielding materials with ultrahigh shielding
effectiveness (SE) are highly desirable for high‐speed electronic devices to attenuate radiated …
effectiveness (SE) are highly desirable for high‐speed electronic devices to attenuate radiated …
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma
…, C Wang, Q Yang, W Liu, Y Wang, Z Wu… - Blood, The Journal …, 2020 - ashpublications.org
Chimeric antigen receptor (CAR) T cells targeting CD19 have achieved breakthroughs in
the treatment of hematological malignancies, such as relapsed/refractory non-Hodgkin …
the treatment of hematological malignancies, such as relapsed/refractory non-Hodgkin …
CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
Y Wang, M Chen, Z Wu, C Tong, H Dai, Y Guo… - …, 2018 - Taylor & Francis
Expressed by cancer stem cells of various epithelial cell origins, CD133 is an attractive
therapeutic target for cancers. Autologous chimeric antigen receptor-modified T-cell directed …
therapeutic target for cancers. Autologous chimeric antigen receptor-modified T-cell directed …
lncRNAs: insights into their function and mechanics in underlying disorders
X Li, Z Wu, X Fu, W Han - Mutation Research/Reviews in Mutation …, 2014 - Elsevier
Genomes of complex organisms are characterized by the pervasive expression of different
types of noncoding RNAs (ncRNAs). lncRNAs constitute a large family of long—arbitrarily …
types of noncoding RNAs (ncRNAs). lncRNAs constitute a large family of long—arbitrarily …
[HTML][HTML] Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
H Dai, Z Wu, H Jia, C Tong, Y Guo, D Ti, X Han… - Journal of hematology & …, 2020 - Springer
Background Despite the impressive complete remission (CR) induced by CD19 CAR-T cell
therapy in B-ALL, the high rate of complete responses is sometimes limited by the …
therapy in B-ALL, the high rate of complete responses is sometimes limited by the …
Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers
K Feng, Y Liu, Y Guo, J Qiu, Z Wu, H Dai, Q Yang… - Protein & …, 2018 - academic.oup.com
This phase I clinical trial (NCT01935843) is to evaluate the safety, feasibility, and activity of
chimeric antigen receptor-engineered T cell (CART) immunotherapy targeting human …
chimeric antigen receptor-engineered T cell (CART) immunotherapy targeting human …